---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-057394"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2025-12-16T23:59:59+00:00"
generated_at: "2026-05-16T13:04:26.872910+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vir Bio licenses CHD combo to Norgine for EUR 55M upfront, up to EUR 495M milestones; cash runway extended to Q4 2027

## Summary
- Exclusive commercial license for tobevibart+elebsiran in Europe, Australia, New Zealand for chronic hepatitis delta.
- Vir receives EUR 55M upfront, up to EUR 495M in milestones, plus tiered mid-teen to high-twenties % royalties.
- Norgine to cover ~25% of go-forward external costs for ECLIPSE registrational program.
- SOLSTICE Phase 2 data: 66% of CHD patients achieved HDV RNA target not detected at 48 weeks; well-tolerated.
- Vir expects current cash, equivalents, and investments to extend into Q4 2027 under current operating plan.

## SEC filing metadata
- accession: 0001628280-25-057394
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2025-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828025057394/0001628280-25-057394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828025057394/vir-20251216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-057394
- JSON: https://secwatch.observer/filing/0001628280-25-057394.json
- Plain text: https://secwatch.observer/filing/0001628280-25-057394.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.